Coxia^®

Coxia is the preparation of Etoricoxib, an NSAID that exhibits anti-inflammatory, analgesic and antipyretic activities. It is a potent, highly selective COX-2 inhibitor. COX-2 is primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Selective inhibition of COX-2 decreases the clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.

No Data

Coxia is indicated for relief of pain and inflammation in:

• Acute & chronic osteoarthritis                    • Chronic musculoskeletal disorders
• Acute & chronic rheumatoid arthritis      • Dysmenorrhoea
• Acute gout arthritis                                         • Chronic low back pain
• Ankylosing spondylitis                                  • Following dental surgery 

Route of administration: Coxia should be taken in oral route.
Osteoarthritis: 30 mg once daily. Dose can be increased to 60 mg once daily.
Chronic musculoskeletal disorder, dysmenorrhea & chronic low back pain: 60 mg once daily.
Rheumatoid arthritis & ankylosing spondylitis: 90 mg once daily.
Acute gout & following dental surgery: 120 mg once daily

Hepatic impairment
In patients with mild hepatic impairment (Child-Pugh score 5-6), a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic impairment (Child-Pugh score 7-9), the dose of 60 mg every other day should not be exceeded; administration of 30 mg once daily can also be considered. Coxia is contraindicated in patients with severe hepatic impairment (Child-Pugh score ≥10).

Pregnancy: Etoricoxib is contraindicated in pregnancy. If a woman becomes pregnant during treatment, etoricoxib must be discontinued.

Lactation: It is not known whether this drug is excreted in human milk.

Use in children and adolescents
Safety and effectiveness in children and adolescents below 16 years of age have not been established.

Caution should be taken in patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients with a prior history of gastrointestinal disease, dehydration and patients with significant risk factors for cardiovascular events. Monitoring of renal function should be ensured in patients with compromised renal perfusion. Etoricoxib can cause fluid retention, oedema, hypertension and elevation in ALT and AST.

The most common side effects are oedema/fluid retention, dizziness, headache, palpitations, hypertension, gastrointestinal disorder and ecchymosis.

It is contraindicated in patients with known hypersensitivity to etoricoxib or any other components of this product. It is also contraindicated in patients with active peptic ulceration or gastrointestinal (Gl) bleeding, patients with creatinine clearance <30 ml/min, patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of acetylsalicylic acid or other NSAIDs, patient having inflammatory bowel disease and congestive heart failure.

Drug interaction with medication: Caution should be taken in concomitant use with oral anticoagulants, diuretics, other NSAIDs, ACE inhibitors, angiotensin II antagonists, lithium, methotrexate, rifampicin, oral contraceptive and HRT.

Drug interaction with food and others: Not applicable.

In case of overdose, general supportive measures and proper monitoring should be initiated.

No Data

Store in a cool and dry place. Protect from light.

Coxia 60 mg tablet: Each coated tablet contains Etoricoxib INN 60 mg.
Coxia 90 mg tablet: Each coated tablet contains Etoricoxib INN 90 mg.
Coxia 120 mg tablet: Each coated tablet contains Etoricoxib INN 120 mg.

Storage
Store below 30°C in a dry place, protected from light. Keep away from the reach of children.

Packing
Coxia 60 mg tablet: Carton of 30 tablets in blister pack.
Coxia 90 mg tablet: Carton of 30 tablets in blister pack.
Coxia 120 mg tablet: Carton of 20 tablets in blister pack.